{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T13:21:06Z","timestamp":1794057666489,"version":"4.8.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-025-04551-w","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T12:49:14Z","timestamp":1746708554000},"page":"3933-3941","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Analysis of gray zone PSA and PSAD correlated with PIRADS v2.1 in the MRI-US fusion prostate biopsy era: a retrospective bi-centre study"],"prefix":"10.1007","volume":"57","author":[{"given":"Michelangelo S.","family":"Cobangbang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryian P.","family":"Paner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome Kyle R.","family":"San Jose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel Antonio D.","family":"Isada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul Anthony L.","family":"Sunga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,8]]},"reference":[{"issue":"3","key":"4551_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660. (Epub 2021 Feb 4 PMID: 33538338)","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"4551_CR2","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1186\/s12885-021-08216-6","volume":"21","author":"J Lee","year":"2021","unstructured":"Lee J, Yang SW, Jin L, Lee CL, Lee JY, Shin JH, Lim JS, Song KH (2021) Is PSA density of the peripheral zone as a useful predictor for prostate cancer in patients with gray zone PSA levels? BMC Cancer 21(1):472. https:\/\/doi.org\/10.1186\/s12885-021-08216-6. (PMID: 33910525; PMCID: PMC8082970)","journal-title":"BMC Cancer"},{"issue":"6","key":"4551_CR3","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.urolonc.2011.06.012","volume":"31","author":"P Tang","year":"2013","unstructured":"Tang P, Du W, Xie K, Deng X, Fu J, Chen H, Yang W (2013) Transition zone PSA density improves the prostate cancer detection rate both in PSA 4.0\u201310.0 and 10.1\u201320.0 ng\/ml in Chinese men. Urol Oncol 31(6):744\u2013748. https:\/\/doi.org\/10.1016\/j.urolonc.2011.06.012. (Epub 2011 Aug 24 PMID: 21868261)","journal-title":"Urol Oncol"},{"issue":"1","key":"4551_CR4","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41391-017-0024-7","volume":"21","author":"T Nordstr\u00f6m","year":"2018","unstructured":"Nordstr\u00f6m T, Akre O, Aly M, Gr\u00f6nberg H, Eklund M (2018) Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer. Prostate Cancer Prostatic Dis 21(1):57\u201363. https:\/\/doi.org\/10.1038\/s41391-017-0024-7. (Epub 2017 Dec 19 PMID: 29259293)","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"11","key":"4551_CR5","doi-asserted-by":"publisher","first-page":"693684","DOI":"10.3389\/fonc.2021.693684","volume":"20","author":"SM Bruno","year":"2021","unstructured":"Bruno SM, Falagario UG, d\u2019Altilia N, Recchia M, Mancini V, Selvaggio O, Sanguedolce F, Del Giudice F, Maggi M, Ferro M, Porreca A, Sciarra A, De Berardinis E, Bettocchi C, Busetto GM, Cormio L, Carrieri G (2021) PSA density help to identify patients with elevated PSA due to prostate cancer rather than intraprostatic inflammation: a prospective single center study. Front Oncol 20(11):693684. https:\/\/doi.org\/10.3389\/fonc.2021.693684. (PMID:34094990;PMCID:PMC8173030)","journal-title":"Front Oncol"},{"issue":"11","key":"4551_CR6","doi-asserted-by":"publisher","first-page":"490.e1","DOI":"10.1016\/j.urolonc.2022.08.003","volume":"40","author":"J Drevik","year":"2022","unstructured":"Drevik J, Dalimov Z, Uzzo R, Danella J, Guzzo T, Belkoff L, Raman J, Tomaszewski J, Trabulsi E, Reese A, Singer EA, Syed K, Jacobs B, Correa A, Smaldone M, Ginzburg S (2022) Utility of PSA density in patients with PI-RADS 3 lesions across a large multi-institutional collaborative. Urol Oncol 40(11):490.e1-490.e6. https:\/\/doi.org\/10.1016\/j.urolonc.2022.08.003. (Epub 2022 Sep 23 PMID: 36163229)","journal-title":"Urol Oncol"},{"issue":"12","key":"4551_CR7","doi-asserted-by":"publisher","first-page":"5705","DOI":"10.21873\/anticanres.16776","volume":"43","author":"Y Fukui","year":"2023","unstructured":"Fukui Y, Yamada Y, Sakamoto S, Horikoshi T, Zhao X, Sato K, Nanba S, Kubota Y, Kanesaka M, Fujimoto A, Shibata H, Goto Y, Sazuka T, Imamura Y, Uno T, Ichikawa T (2023) Preoperative PI-RADS v2.1 scoring system improves risk classification in patients undergoing radical prostatectomy. Anticancer Res 43(12):5705\u20135712. https:\/\/doi.org\/10.21873\/anticanres.16776. (PMID: 38030183)","journal-title":"Anticancer Res"},{"issue":"12","key":"4551_CR8","doi-asserted-by":"publisher","first-page":"4142","DOI":"10.1007\/s00261-020-02724-y","volume":"45","author":"Z Wang","year":"2020","unstructured":"Wang Z, Zhao W, Shen J, Jiang Z, Yang S, Tan S, Zhang Y (2020) PI-RADS version 2.1 scoring system is superior in detecting transition zone prostate cancer: a diagnostic study. Abdom Radiol (NY) 45(12):4142\u20134149. https:\/\/doi.org\/10.1007\/s00261-020-02724-y. (Epub 2020 Sep 9 PMID: 32902659)","journal-title":"Abdom Radiol (NY)"},{"key":"4551_CR9","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.23.29964","author":"EC Yilmaz","year":"2023","unstructured":"Yilmaz EC, Lin Y, Belue MJ, Harmon SA, Phelps TE, Merriman KM, Hazen LA, Garcia C, Johnson L, Lay NS, Toubaji A, Merino MJ, Patel KR, Parnes HL, Law YM, Wood BJ, Gurram S, Choyke PL, Pinto PA, Turkbey B (2023) PI-RADS version 2.0 versus version 2.1: comparison of prostate cancer gleason grade upgrade and downgrade rates from MRI-targeted biopsy to radical prostatectomy. Am J Roentgenol. https:\/\/doi.org\/10.2214\/AJR.23.29964","journal-title":"Am J Roentgenol"},{"issue":"S2","key":"4551_CR10","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1089\/end.2020.1075","volume":"35","author":"JS Jue","year":"2021","unstructured":"Jue JS, Rastinehad AR (2021) MRI fusion transperineal prostate biopsy instructions and troubleshooting. J Endourol 35(S2):S2\u2013S6. https:\/\/doi.org\/10.1089\/end.2020.1075. (PMID: 34499560)","journal-title":"J Endourol"},{"issue":"3","key":"4551_CR11","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1002\/jmri.28614","volume":"58","author":"Y Liu","year":"2023","unstructured":"Liu Y, Wang S, Xu G, Zhou B, Zhang Y, Ye B, Xiang L, Zhang Y, Xu H (2023) Effectiveness and accuracy of MRI-ultrasound fusion targeted biopsy based on PI-RADS v2.1 category in transition\/peripheral zone of the prostate. J Magn Reson Imaging: JMRI 58(3):709\u2013717. https:\/\/doi.org\/10.1002\/jmri.28614","journal-title":"J Magn Reson Imaging: JMRI"},{"issue":"11","key":"4551_CR12","doi-asserted-by":"publisher","first-page":"846.e9","DOI":"10.1016\/j.urolonc.2020.05.024","volume":"38","author":"E Stevens","year":"2020","unstructured":"Stevens E, Truong M, Bullen JA, Ward RD, Purysko AS, Klein EA (2020) Clinical utility of PSAD combined with PI-RADS category for the detection of clinically significant prostate cancer. Urol Oncol 38(11):846.e9-846.e16. https:\/\/doi.org\/10.1016\/j.urolonc.2020.05.024","journal-title":"Urol Oncol"},{"issue":"2","key":"4551_CR13","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/s41391-022-00549-y","volume":"26","author":"JW Frisbie","year":"2023","unstructured":"Frisbie JW, Van Besien AJ, Lee A, Xu L, Wang S, Choksi A, Afzal MA, Naslund MJ, Lane B, Wong J, Wnorowski A, Siddiqui MM (2023) PSA density is complementary to prostate MP-MRI PI-RADS scoring system for risk stratification of clinically significant prostate cancer. Prostate Cancer Prostatic Dis 26(2):347\u2013352. https:\/\/doi.org\/10.1038\/s41391-022-00549-y","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"7","key":"4551_CR14","doi-asserted-by":"publisher","first-page":"431.e9","DOI":"10.1016\/j.urolonc.2020.11.010","volume":"39","author":"L Rico","year":"2021","unstructured":"Rico L, Blas L, Vitagliano G, Contreras P, Rios Pita H, Ameri C (2021) PI-RADS 3 lesions: Does the association of the lesion volume with the prostate-specific antigen density matter in the diagnosis of clinically significant prostate cancer? Urol Oncol 39(7):431.e9-431.e13. https:\/\/doi.org\/10.1016\/j.urolonc.2020.11.010. (Epub 2020 Nov 19 PMID: 33221259)","journal-title":"Urol Oncol"},{"issue":"1","key":"4551_CR15","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s10147-019-01524-9","volume":"25","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Zeng N, Zhang F, Huang Y, Tian Y (2020) How to make clinical decisions to avoid unnecessary prostate screening in biopsy-na\u00efve men with PI-RADs v2 score \u2264 3? Int J Clin Oncol 25(1):175\u2013186. https:\/\/doi.org\/10.1007\/s10147-019-01524-9. (Epub 2019 Aug 31 PMID: 31473884)","journal-title":"Int J Clin Oncol"},{"issue":"2","key":"4551_CR16","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","volume":"86","author":"P Cornford","year":"2024","unstructured":"Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, Eberli D, De Meerleer G, De Santis M, Farolfi A, Gandaglia G, Gillessen S, Grivas N, Henry AM, Lardas M, van Leenders GJLH, Liew M, Linares Espinos E, Oldenburg J, van Oort IM, Oprea-Lager DE, Ploussard G, Roberts MJ, Rouvi\u00e8re O, Schoots IG, Schouten N, Smith EJ, Stranne J, Wiegel T, Willemse PM, Tilki D (2024) EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer-2024 update. part I: screening, diagnosis, and local treatment with curative intent. Eur Urol 86(2):148\u2013163. https:\/\/doi.org\/10.1016\/j.eururo.2024.03.027. (Epub 2024 Apr 13 PMID: 38614820)","journal-title":"Eur Urol"},{"issue":"1","key":"4551_CR17","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.4102\/sajr.v25i1.2062","volume":"25","author":"R Scott","year":"2021","unstructured":"Scott R, Misser SK, Cioni D, Neri E (2021) PI-RADS v2.1: what has changed and how to report. SA J Radiol 25(1):2062. https:\/\/doi.org\/10.4102\/sajr.v25i1.2062. (PMID: 34230862; PMCID: PMC8252188)","journal-title":"SA J Radiol"},{"issue":"5","key":"4551_CR18","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.21037\/tau-20-1154","volume":"9","author":"Z Ding","year":"2020","unstructured":"Ding Z, Wu H, Song D, Tian H, Ye X, Liang W, Jiao Y, Hu J, Xu J, Dong F (2020) Development and validation of a nomogram for predicting prostate cancer in men with prostate-specific antigen grey zone based on retrospective analysis of clinical and multi-parameter magnetic resonance imaging\/transrectal ultrasound fusion-derived data. Transl Androl Urol 9(5):2179\u20132191. https:\/\/doi.org\/10.21037\/tau-20-1154. (PMID:33209682;PMCID:PMC7658138)","journal-title":"Transl Androl Urol"},{"issue":"11","key":"4551_CR19","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1111\/ijcp.12883","volume":"70","author":"T Ross","year":"2016","unstructured":"Ross T, Ahmed K, Raison N, Challacombe B, Dasgupta P (2016) Clarifying the PSA grey zone: the management of patients with a borderline PSA. Int J Clin Pract 70(11):950\u2013959. https:\/\/doi.org\/10.1111\/ijcp.12883. (Epub 2016 Sep 27 PMID: 27672001)","journal-title":"Int J Clin Pract"},{"issue":"1","key":"4551_CR20","doi-asserted-by":"publisher","first-page":"5157","DOI":"10.1038\/s41598-020-62015-w.","volume":"10","author":"J Liu","year":"2020","unstructured":"Liu J, Dong B, Qu W, Wang J, Xu Y, Yu S, Zhang X (2020) Using clinical parameters to predict prostate cancer and reduce the unnecessary biopsy among patients with PSA in the gray zone. Sci Rep 10(1):5157. https:\/\/doi.org\/10.1038\/s41598-020-62015-w. (PMID:32198373;PMCID:PMC7083895)","journal-title":"Sci Rep"},{"issue":"12","key":"4551_CR21","doi-asserted-by":"publisher","first-page":"e6329","DOI":"10.7759\/cureus.6329","volume":"11","author":"G S\u00f6nmez","year":"2019","unstructured":"S\u00f6nmez G, Tombul \u015eT, Demirta\u015f T, \u00d6zt\u00fcrk F, Demirta\u015f A (2019) A comparative study: has MRI-guided fusion prostate biopsy changed the prostate-specific antigen gray-zone range? Cureus 11(12):e6329. https:\/\/doi.org\/10.7759\/cureus.6329. (PMID:31857929;PMCID:PMC6901373)","journal-title":"Cureus"},{"issue":"26","key":"4551_CR22","doi-asserted-by":"publisher","first-page":"e16289","DOI":"10.1097\/MD.0000000000016289","volume":"98","author":"YF Lu","year":"2019","unstructured":"Lu YF, Zhang Q, Chen HY, Chen JY, Pan Y, Xu CC, Xu JX, Yu RS (2019) Improving the detection rate of prostate cancer in the gray zone of PI-RADS v2 and serum tPSA by using prostate-specific antigen-age volume. Medicine (Baltimore) 98(26):e16289. https:\/\/doi.org\/10.1097\/MD.0000000000016289. (PMID:31261602;PMCID:PMC6616591)","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"4551_CR23","doi-asserted-by":"publisher","first-page":"6570","DOI":"10.1038\/s41598-024-57337-y","volume":"14","author":"J Wen","year":"2024","unstructured":"Wen J, Liu W, Shen X, Hu W (2024) PI-RADS v2.1 and PSAD for the prediction of clinically significant prostate cancer among patients with PSA levels of 4\u201310 ng\/ml. Sci Rep 14(1):6570. https:\/\/doi.org\/10.1038\/s41598-024-57337-y. (PMID: 38503972; PMCID: PMC10951302)","journal-title":"Sci Rep"},{"issue":"9","key":"4551_CR24","doi-asserted-by":"publisher","first-page":"407.e21","DOI":"10.1016\/j.urolonc.2022.06.005","volume":"40","author":"SD Lokeshwar","year":"2022","unstructured":"Lokeshwar SD, Nguyen J, Rahman SN, Khajir G, Ho R, Ghabili K, Leapman MS, Weinreb JC, Sprenkle PC (2022) Clinical utility of MR\/ultrasound fusion-guided biopsy in patients with lower suspicion lesions on active surveillance for low-risk prostate cancer. Urol Oncol 40(9):407.e21-407.e27. https:\/\/doi.org\/10.1016\/j.urolonc.2022.06.005. (Epub 2022 Jul 8 PMID: 35811206)","journal-title":"Urol Oncol"},{"key":"4551_CR25","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/bju.15277","volume":"127","author":"IG Schoots","year":"2021","unstructured":"Schoots IG, Padhani AR (2021) Risk-adapted biopsy decision based on prostate magnetic resonance imaging and prostate-specific antigen density for enhanced biopsy avoidance in first prostate cancer diagnostic evaluation. BJU Int 127:175\u2013178. https:\/\/doi.org\/10.1111\/bju.15277","journal-title":"BJU Int"},{"issue":"11","key":"4551_CR26","doi-asserted-by":"publisher","first-page":"e059482","DOI":"10.1136\/bmjopen-2021-059482","volume":"12","author":"R Nam","year":"2022","unstructured":"Nam R, Patel C, Milot L, Hird A, Wallis C, Macinnis P, Singh M, Emmenegger U, Sherman C, Haider MA (2022) Prostate MRI versus PSA screening for prostate cancer detection (the MVP Study): a randomised clinical trial. BMJ Open 12(11):e059482. https:\/\/doi.org\/10.1136\/bmjopen-2021-059482. (PMID:36351725;PMCID:PMC9644313)","journal-title":"BMJ Open"},{"issue":"3","key":"4551_CR27","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1038\/s41391-021-00330-7","volume":"24","author":"PK Kuhlmann","year":"2021","unstructured":"Kuhlmann PK, Chen M, Luu M, Naser-Tavakolian A, Patel DN, Kim HL, Saouaf R, Daskivich TJ (2021) Patient- and tumor-level risk factors for MRI-invisible prostate cancer. Prostate Cancer Prostatic Dis 24(3):794\u2013801. https:\/\/doi.org\/10.1038\/s41391-021-00330-7. (Epub 2021 Feb 10 PMID: 33568751)","journal-title":"Prostate Cancer Prostatic Dis"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04551-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-025-04551-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04551-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T18:08:47Z","timestamp":1761847727000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-025-04551-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,8]]},"references-count":27,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4551"],"URL":"https:\/\/doi.org\/10.1007\/s11255-025-04551-w","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,8]]},"assertion":[{"value":"23 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Institutional Ethics Review Committee of St. Luke\u2019s Medical Center, Philippines (Approval No: SL-23070).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"N\/A.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"N\/A.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human and\/or animals participants"}},{"value":"N\/A.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Registry and the registration no. of the study\/trial"}}]}}